Business

US-based Paratek Pharmaceuticals will acquire all outstanding shares of intranasal drug developer Optinose in a deal worth up to $330 million, the companies said. According to the announcement, both companies' boards have approved the deal, which could close by mid-2025. Paratek will pay $9 per share up front plus up to an additional $5 per share in milestone payments … [Read more...] about Paratek to acquire Optinose

DPI developer Chance Pharmaceuticals announced the completion of a financing round with participation from Heda Health Fund and Qihang Venture Capital, with proceeds intended to support Phase 3 trials of CXG87 inhaled dry powder budesonide / formoterol as well as development of some additional DPI formulations. The company did not specify the amount raised. Chance … [Read more...] about Chance Pharma announces funding to support Phase 3 trial of CXG87 budesonide / formoterol DPI

Israeli biotech Polyrizon announced that it is beginning preclinical development of an intranasal naloxone formulation based on the company's Trap and Target mucoadhesive technology. The company said that Fabio Sonvico of the University of Parma, who is a member of Polyrizon's scientific advisory board, will conduct the studies. Polyrizon CEO Tomer Izraeli … [Read more...] about Polyrizon announces development of intranasal naloxone and agreement to develop intranasal formulation of a psychedelic therapy

Armata Pharmaceuticals announced details of an additional secured credit agreement with Innoviva Strategic Opportunities, the company's largest shareholder. Armata said that it will pay interest at a 14% annual rate on the $10 million loan which matures on March 12, 2026. According to the announcement, the funds will be used for continued development of candidates … [Read more...] about Armata announces $10 million loan from Innoviva to fund development of candidates including AP-PA02 inhaled phage therapy

Emergent BioSolutions and Swiss biotech Rocketvax have announced that Emergent will make a strategic investment in Rocketvax parent company Swiss Rockets and will take over manufacturing and commercialization activities for 4 of Rocketvax's intranasal vaccine candidates. Rocketvax's pipeline includes live attenuated intranasal vaccines for melanoma and multiple … [Read more...] about Emergent BioSolutions and Rocketvax form joint venture for development of intranasal vaccine candidates

Altamira Therapeutics said that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent covering the formulation of Bentrio bentonite-based nasal spray. Bentrio received 510(k) clearance in the US in June 2022. In 2023, the company sold a 51% stake in its subsidiary Altamira Medica, which developed Bentrio for the prevention … [Read more...] about Altamira gets US patent covering Bentrio bentonite nasal spray formulation

According to DPI developer Iconovo, the company has received a grant worth SEK 670,000 from the EU's Innowwide initiative, which encourages small and medium-sized EU companies to enter international markets. The grant will fund a market study this year that will evaluate opportunities for Iconovo to partner with Japanese companies to sell its products and services in … [Read more...] about Iconovo gets SEK 670,000 Innowwide grant to explore selling its DPIs and services in the Japanese market

According to Silo Pharma, the US Patent and Trademark Office (USPTO) has indicated that it will issue a new patent on March 4, 2025 that will provide protection for Silo's SPC-15 intranasal ketamine. The company says that the expected patent number for the patent titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females” is … [Read more...] about Silo Pharma announces additional US patent related to SPC-15 intranasal ketamine